Authors

Latest:

Dr. Danciu on Prescreening and Identifying Breast Cancer Survivors

Oana C. Danciu, MD, assistant professor of Medicine, Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, discusses a study examining a team-based approach to prescreen and identify breast cancer survivors using a survivorship care plan.

OBTN

Latest:

December 2011: Trials in Progress

The Trials in Progress section supploes summaries of ongoing research in a broad range of cancer types.

Ola Landgren, MD, PhD

Latest:

Dr Landgren on the Management of Newly Diagnosed Multiple Myeloma Treatment

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center

Olga Frankfurt, MD

Latest:

Dr. Frankfurt on the Future of AML Treatments

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Oliver Dorigo, MD, PhD

Latest:

Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian Cancer

Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.

Oliver Dorigo, MD, PhD, Stanford University Medical Center

Oliver Sartor, MD

Latest:

Dr Sartor on Ongoing Prostate Cancer Research

Oliver Sartor, MD, discusses ongoing prostate cancer research, highlighting the importance of considering patient quality of life.

Oliver Waidmann, MD, Goethe-Universitat Frankfurt am Main

Oliver Zill

Latest:

Next-Generation Sequencing Analysis of Circulating Tumor DNA

Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

Oliver Zivanovic, MD, Dennis S. Chi, MD

Latest:

HIPEC for Ovarian Cancer: An Exciting Locoregional Strategy

Approximately 22,000 women will be diagnosed with epithelial ovarian cancer (EOC) in the United States in 2014, making it the nation's second most common gynecologic malignancy.1 The cancer, which often presents at an advanced stage, causes more deaths than any other type of gynecologic malignancy.

Olivia Pagani, MD

Latest:

Dr. Pagani Discusses Aromatase Inhibitors for Premenopausal Women with Breast Cancer

Olivia Pagani, MD, Institute of Oncology, Southern Switzerland, discusses the result of a joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptorâ€“positive (HR+) breast cancer who were treated with the aromatase inhibitor exemestane.

Oludamilola (Lola) A. Olajide, MD

Latest:

Dr. Olopade on Moving the Needle Forward in Preventive Oncology and Genetics

Olufunmilayo I. Olopade, MD, FACP, discusses the need to focus efforts in preventive oncology and genetics.

Omar Al Ustwani, MD

Latest:

Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia

Abelson tyrosine kinase (ABL1) is a nonreceptor tyrosine kinase involved in cell growth and proliferation.

Omar Hafez, MS, MBA

Latest:

Signs Point to Better Market Conditions for Biosimilars

Even though many challenges must be overcome before widespread adoption can occur, there is still much promise on the horizon for biosimilars.

Omar Nadeem, MD

Latest:

Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma

Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.

Omid A. Hamid, MD

Latest:

Dr Hamid on the Investigation of Fianlimab With Cemiplimab in Advanced Melanoma

Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.

Omid Hamid, MD

Latest:

Dr Hamid on Addressing Unmet Needs in Relapsed Melanoma With Lifileucel

Omid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.

Omid Hamid, MD, Angeles Clinic

Omid Hamid, MD, The Angeles Clinic